Recombinant interleukin-6 - Relief Therapeutics Holding

Drug Profile

Recombinant interleukin-6 - Relief Therapeutics Holding

Alternative Names: atexakin alfa; r-IL-6

Latest Information Update: 26 Oct 2016

Price : $50

At a glance

  • Originator Merck Serono; Weizmann Institute of Science
  • Developer FirstString Research; RELIEF THERAPEUTICS Holding
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Interleukin 6 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic neuropathies; Peripheral nerve injuries

Most Recent Events

  • 26 Oct 2016 Relief Therapeutics and FirstString Research collaborates for the clinical development of recombinant interleukin-6 (atexakin alfa) in USA
  • 26 Oct 2016 Phase-II clinical trials in Diabetic neuropathies in USA (unspecified route) (Relief Therapeutics pipeline; October 2016)
  • 25 Oct 2016 Relief Therapeutics plans a phase II trial in Diabetic neuropathy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top